State Street Corp Allogene Therapeutics, Inc. Transaction History

State Street Corp

$2.41 Trillion
Q3 2024

A detailed history of State Street Corp transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, State Street Corp holds 7,013,083 shares of ALLO stock, worth $13.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

7,013,083

Previous 7,668,124 8.54%

Holding current value

$13.4 Million

Previous $17.9 Million 9.91%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$2.08 - $3.5 $1.36 Million - $2.29 Million	-655,041 Reduced 8.54%	7,013,083 $19.6 Million
Q2 2024 Aug 14, 2024	SELL	$2.23 - $4.38 $3.38 Million - $6.64 Million	-1,515,887 Reduced 16.51%	7,668,124 $17.9 Million
Q1 2024 May 15, 2024	BUY	$2.92 - $5.63 $19.7 Million - $38 Million	6,756,727 Added 278.37%	9,184,011 $41.1 Million
Q4 2023 Feb 14, 2024	SELL	$2.28 - $3.5 $13.2 Million - $20.2 Million	-5,775,317 Reduced 70.41%	2,427,284 $7.79 Million
Q3 2023 Nov 14, 2023	SELL	$3.17 - $5.96 $875,427 - $1.65 Million	-276,160 Reduced 3.26%	8,202,601 $26 Million
Q2 2023 Aug 14, 2023	BUY	$4.53 - $6.74 $1.21 Million - $1.8 Million	267,687 Added 3.26%	8,478,761 $42.1 Million
Q1 2023 May 15, 2023	SELL	$4.92 - $8.21 $4.7 Million - $7.84 Million	-955,334 Reduced 10.42%	8,211,074 $40.6 Million
Q4 2022 Feb 14, 2023	BUY	$5.62 - $11.11 $14 Million - $27.6 Million	2,486,111 Added 37.22%	9,166,408 $57.7 Million
Q3 2022 Nov 15, 2022	BUY	$10.32 - $17.28 $10.6 Million - $17.7 Million	1,025,973 Added 18.14%	6,680,297 $72.1 Million
Q2 2022 Aug 15, 2022	SELL	$6.78 - $12.28 $15.1 Million - $27.3 Million	-2,223,324 Reduced 28.22%	5,654,324 $64.5 Million
Q1 2022 May 16, 2022	BUY	$7.65 - $15.29 $26.5 Million - $53 Million	3,464,603 Added 78.51%	7,877,648 $71.8 Million
Q4 2021 Feb 14, 2022	BUY	$13.13 - $24.52 $11.8 Million - $22.1 Million	899,729 Added 25.61%	4,413,045 $65.8 Million
Q3 2021 Nov 15, 2021	BUY	$21.01 - $27.64 $10.7 Million - $14.1 Million	508,416 Added 16.92%	3,513,316 $90.3 Million
Q2 2021 Aug 16, 2021	BUY	$23.49 - $35.8 $15.8 Million - $24 Million	671,104 Added 28.76%	3,004,900 $78.4 Million
Q1 2021 May 17, 2021	SELL	$25.79 - $39.02 $26.8 Million - $40.6 Million	-1,039,665 Reduced 30.82%	2,333,796 $82.4 Million
Q4 2020 Feb 16, 2021	BUY	$25.24 - $43.45 $20.4 Million - $35.2 Million	809,829 Added 31.59%	3,373,461 $85.1 Million
Q3 2020 Nov 10, 2020	BUY	$32.38 - $44.96 $9.9 Million - $13.8 Million	305,841 Added 13.55%	2,563,632 $96.7 Million
Q2 2020 Aug 14, 2020	BUY	$18.39 - $54.04 $10.4 Million - $30.5 Million	563,575 Added 33.26%	2,257,791 $96.7 Million
Q1 2020 May 11, 2020	BUY	$18.22 - $28.25 $30.9 Million - $47.9 Million	1,694,216 New	1,694,216 $32.9 Million

Others Institutions Holding ALLO

# of Institutions

162

Shares Held

134M

Call Options Held

59.4K

Put Options Held

113K

View Full List

About Allogene Therapeutics, Inc.

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $275M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

More about ALLO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.

Account

State Street Corp Allogene Therapeutics, Inc. Transaction History